Patents Assigned to Amgen
  • C3b/C4b complement receptor-like molecules and uses thereof
    Patent number: 6656707
    Abstract: Novel C3b/C4b CR-like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing C3b/C4b CR-like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with C3b/C4b CR-like polypeptides.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: December 2, 2003
    Assignee: Amgen Inc.
    Inventors: Andrew A. Welcher, Gary S. Elliott
  • Sustained-release alginate gels
    Patent number: 6656508
    Abstract: The present invention relates to sustained-release formulations using alginate gel beads and methods thereof.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: December 2, 2003
    Assignee: Amgen Inc.
    Inventors: Merrill Seymour Goldenberg, Alice C. Beekman
  • Antibodies which activate an erythropoietin receptor
    Publication number: 20030215444
    Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.
    Type: Application
    Filed: February 10, 2003
    Publication date: November 20, 2003
    Applicant: Amgen Inc.
    Inventor: Steven G. Elliott
  • Substituted pyridone compounds and methods of use
    Patent number: 6649604
    Abstract: Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: November 18, 2003
    Assignee: Amgen Inc.
    Inventors: Ulrike D. Spohr, Michael J. Malone, Nathan B. Mantlo, Jeffrey A. Zablocki
  • Thiazolyl urea compounds and methods of uses
    Patent number: 6645990
    Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: November 11, 2003
    Assignee: Amgen Inc.
    Inventors: Benny C. Askew, Frenel F. De Morin, Andrew Hague, Ellen Laber, Aiwen Li, Gang Liu, Patricia Lopez, Rana Nomak, Vincent Santora, Christopher Tegley, Kevin Yang
  • Beta-like glycoprotein hormone polypeptide and heterodimer
    Publication number: 20030207403
    Abstract: Novel &bgr;10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing &bgr;10 polypeptides and heterodimeric forms thereof, specifically &agr;2/&bgr;10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with &bgr;10 polypeptides and &agr;2/&bgr;10 heterodimers or their respective binding agents.
    Type: Application
    Filed: May 28, 2003
    Publication date: November 6, 2003
    Applicant: Amgen Inc.
    Inventors: Christopher J. R. Paszty, Jin Cao, Dimitry M. Danilenko, Jianhua Gong, David C. Hill
  • Chemically modified G-CSF
    Publication number: 20030204057
    Abstract: The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence:
    Type: Application
    Filed: May 12, 2003
    Publication date: October 30, 2003
    Applicant: KIRIN-AMGEN
    Inventors: Rika Ishikawa, Yuji Okada, Makoto Kakitani
  • Substituted amine derivatives and methods of use
    Publication number: 20030203922
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: July 17, 2002
    Publication date: October 30, 2003
    Applicant: Amgen Inc.
    Inventors: Vinod F. Patel, Benny Askew, Shon Booker, Guoqing Chen, Lucian V. DiPietro, Julie Germain, Gregory J. Habgood, Qi Huang, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Rana Nomak, Babak Riahi, Chester Chenguang Yuan, Daniel Elbaum
  • Kinase inhibitors
    Publication number: 20030199534
    Abstract: The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.
    Type: Application
    Filed: January 28, 2003
    Publication date: October 23, 2003
    Applicant: Amgen Inc.
    Inventors: David M. Armistead, Jean E. Bemis, Lucian V. DiPietro, Stephanie D. Geuns-Meyer, Gregory J. Habgood, Joseph L. Kim, Joseph J. Nunes, Vinod F. Patel, Leticia M. Toledo-Sherman
  • Peptides and related molecules that bind to TALL-1
    Publication number: 20030195156
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae 1 (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ.
    Type: Application
    Filed: May 13, 2002
    Publication date: October 16, 2003
    Applicant: Amgen Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • G-CSF analog compositions and methods
    Patent number: 6632426
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: October 14, 2003
    Assignee: Amgen Inc.
    Inventor: Timothy David Osslund
  • Enhanced solubility of recombinant proteins using Uracil DNA glycosylase inhibitor
    Patent number: 6632638
    Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with Uracil DNA glycosylase inhibitor (UGI).
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: October 14, 2003
    Assignee: Amgen, Inc.
    Inventors: Marshall Snavely, Lana Klionsky
  • Pegylation reagents and compounds formed therewith
    Publication number: 20030190304
    Abstract: Biologically active conjugates are disclosed which are formed by reaction of a thiol moiety of a biologically active molecule with a non-peptidic polymer having an active sulfone moiety. Also disclosed are compounds having the formula R1—X—R2 wherein at least one of R1 and R2 is a biologically active molecule having a reactive thiol moiety which forms a covalent bond with X, a Michael acceptor-activated non-peptidic polymer. Further disclosed are methods of making the conjugates and compounds of the present invention as well as pharmaceutical compositions containing them. In addition, activated polymers suitable for attachment to a variety of molecules and surfaces are disclosed.
    Type: Application
    Filed: March 27, 2003
    Publication date: October 9, 2003
    Applicant: Amgen Inc.
    Inventors: Robert C. Thompson, Michael T. Brewer, Tadahiko Kohno
  • Methods for the treatment of thrombosis
    Publication number: 20030186422
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Application
    Filed: May 20, 2003
    Publication date: October 2, 2003
    Applicant: AMGEN INC., a Delaware Corporation
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • Chimeric OPG polypeptides
    Publication number: 20030187224
    Abstract: Chimeric polypeptides comprising fusions of an osteoprotegerin dimerization domain to a heterologous sequence are provided. Also provided are nucleic acids encoding the polypeptides, expression vectors and host cells for their production and pharmaceutical compositions comprising the polypeptides.
    Type: Application
    Filed: May 12, 2003
    Publication date: October 2, 2003
    Applicant: Amgen Inc.
    Inventors: William J. Boyle, Scott Wooden
  • Oral delivery of chemically modified proteins
    Publication number: 20030185795
    Abstract: Provided are compositions and methods for oral delivery of chemically modified proteins, including chemically modified G-CSF and chemically modified consensus interferon. Uptake from the intestine to the bloodstream is demonstrated for pegylated G-CSF and pegylated consensus interferon.
    Type: Application
    Filed: January 15, 2003
    Publication date: October 2, 2003
    Applicant: Amgen Inc.
    Inventor: Alan D. Habberfield
  • Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
    Patent number: 6627199
    Abstract: Novel TNF reccptor polypeptides are disclosed, along with polynucleotides encoding the polypeptides and uses thereof.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: September 30, 2003
    Assignee: Amgen Inc
    Inventor: Chris Saris
  • Glial cell line-derived neurotrophic factor receptor
    Publication number: 20030175876
    Abstract: The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling.
    Type: Application
    Filed: May 24, 2002
    Publication date: September 18, 2003
    Applicant: Amgen Inc.
    Inventors: Gary M. Fox, Shuqian Jing, Duanzhi Wen
  • G-protein coupled receptor molecules and uses thereof
    Publication number: 20030171541
    Abstract: The present invention provides G-Protein Coupled Receptor (GPCR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides.
    Type: Application
    Filed: February 14, 2002
    Publication date: September 11, 2003
    Applicant: Amgen Inc., A Corporation of the State of Delaware
    Inventors: Steven G. Elliott, Norma Rogers, Leigh Anne Busse
  • Novel Shc-binding protein
    Publication number: 20030170688
    Abstract: Novel Shc-binding protein, oligonucleotides encoding the same, methods of producing and use thereof are disclosed.
    Type: Application
    Filed: December 10, 2002
    Publication date: September 11, 2003
    Applicant: Amgen Canada, Inc.
    Inventors: Jane McGlade, Rosemary Schmandt